Terms: = Pancreatic cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Treatment
336 results:
1. Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer.
Zeng D; Yu C; Chen S; Zou L; Chen J; Xu L
World J Surg Oncol; 2024 Apr; 22(1):93. PubMed ID: 38605359
[TBL] [Abstract] [Full Text] [Related]
2. Polycyclic Aromatic Hydrocarbons and pancreatic cancer: An Analysis of the Blood Biomarker,
Nguyen S; Carlson H; Yoder A; Bamlet WR; Oberg AL; Petersen GM; Carmella SG; Hecht SS; Jansen RJ
Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474816
[TBL] [Abstract] [Full Text] [Related]
3. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of occult vertebral fracture in patients undergoing pancreatic resection for pancreatic cancer.
Ishizaki S; Furukawa K; Haruki K; Tsunematsu M; Shirai Y; Matsumoto M; Okui N; Onda S; Taniai T; Ikegami T
Pancreatology; 2024 Mar; 24(2):249-254. PubMed ID: 38218681
[TBL] [Abstract] [Full Text] [Related]
5. Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.
Kai M; Hikita H; Kazuki M; Tahata Y; Shinkai K; Doi A; Ohkawa K; Miyazaki M; Ishida H; Matsumoto K; Nozaki Y; Yakushijin T; Sakamori R; Kaneko A; Iio S; Nawa T; Kakita N; Morishita N; Hiramatsu N; Usui T; Imanaka K; Doi Y; Sakakibara M; Yoshida Y; Oze T; Kodama T; Tatsumi T; Takehara T
PLoS One; 2024; 19(1):e0294590. PubMed ID: 38165900
[TBL] [Abstract] [Full Text] [Related]
6. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial.
Melisi D; Zecchetto C; Merz V; Malleo G; Landoni L; Quinzii A; Casalino S; Fazzini F; Gaule M; Pesoni C; Casetti L; Esposito A; Marchegiani G; Piazzola C; D'Onofrio M; de Robertis R; Gabbrielli A; Bernardoni L; Crino SF; Pietrobono S; Luchini C; Aliberti C; Martignoni G; Milleri S; Butturini G; Scarpa A; Salvia R; Bassi C
Eur J Cancer; 2024 Jan; 196():113430. PubMed ID: 37995598
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic Value of Serum α-Fetoprotein Level as an Important Characteristic of Tumor Biology for Patients Undergoing Liver Resection of Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): A Large Multicenter Analysis.
Yao LQ; Fan ZQ; Wang MD; Diao YK; Chen TH; Zeng YY; Chen Z; Wang XM; Zhou YH; Li J; Fan XP; Liang YJ; Li C; Shen F; Lv GY; Yang T
Ann Surg Oncol; 2024 Feb; 31(2):1219-1231. PubMed ID: 37925654
[TBL] [Abstract] [Full Text] [Related]
8. First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
Leidner R; Conlon K; McNeel DG; Wang-Gillam A; Gupta S; Wesolowski R; Chaudhari M; Hassounah N; Lee JB; Ho Lee L; O'Keeffe JA; Lewis N; Pavlakis GN; Thompson JA
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37907221
[TBL] [Abstract] [Full Text] [Related]
9. Laparoscopic Management of Blunt pancreatic Trauma in Adults and Pediatric Patients: A Systematic Review.
Catellani B; Caracciolo D; Magistri P; Guidetti C; Menduni N; Yu H; Odorizzi R; Guerrini GP; Ballarin R; Di Sandro S; Di Benedetto F
Biomed Res Int; 2023; 2023():9296570. PubMed ID: 37810623
[TBL] [Abstract] [Full Text] [Related]
10. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Wainberg ZA; Melisi D; Macarulla T; Pazo Cid R; Chandana SR; De La Fouchardière C; Dean A; Kiss I; Lee WJ; Goetze TO; Van Cutsem E; Paulson AS; Bekaii-Saab T; Pant S; Hubner RA; Xiao Z; Chen H; Benzaghou F; O'Reilly EM
Lancet; 2023 Oct; 402(10409):1272-1281. PubMed ID: 37708904
[TBL] [Abstract] [Full Text] [Related]
11. The Balance Between the Therapeutic Efficacy and Safety of [
Verhoeven M; Haeck J; de Blois E; Orlandi F; Barbato D; Tedesco M; Konijnenberg M; Dalm SU
Mol Imaging Biol; 2024 Feb; 26(1):114-123. PubMed ID: 37640941
[TBL] [Abstract] [Full Text] [Related]
12. NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases.
Kobayashi S; Bando H; Taketomi A; Takamoto T; Shinozaki E; Shiozawa M; Hara H; Yamazaki K; Komori K; Matsuhashi N; Kato T; Kagawa Y; Yokota M; Oki E; Komine K; Takahashi S; Wakabayashi M; Yoshino T
BMC Cancer; 2023 Aug; 23(1):779. PubMed ID: 37605122
[TBL] [Abstract] [Full Text] [Related]
13. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial.
van Dam JL; Verkolf EMM; Dekker EN; Bonsing BA; Bratlie SO; Brosens LAA; Busch OR; van Driel LMJW; van Eijck CHJ; Feshtali S; Ghorbani P; de Groot DJA; de Groot JWB; Haberkorn BCM; de Hingh IH; van der Holt B; Karsten TM; van der Kolk MB; Labori KJ; Liem MSL; Loosveld OJL; Molenaar IQ; Polée MB; van Santvoort HC; de Vos-Geelen J; Wumkes ML; van Tienhoven G; Homs MYV; Besselink MG; Wilmink JW; Groot Koerkamp B;
BMC Cancer; 2023 Aug; 23(1):728. PubMed ID: 37550634
[TBL] [Abstract] [Full Text] [Related]
14. From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification.
Fan Z; Jin M; Zhang L; Wang N; Li M; Wang C; Wei F; Zhang P; Du X; Sun X; Qiu W; Wang M; Wang H; Shi X; Ye J; Jiang C; Zhou J; Chai W; Qi J; Li T; Zhang R; Liu X; Huang B; Chai K; Cao Y; Mu W; Huang Y; Yang T; Zhang H; Qu L; Liu Y; Wang G; Lv G
Gut; 2023 Nov; 72(11):2149-2163. PubMed ID: 37549980
[TBL] [Abstract] [Full Text] [Related]
15. Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients.
Lin KY; Lin ZW; Chen QJ; Luo LP; Zhang JX; Chen JH; Wang K; Tai S; Zhang ZB; Wang SF; Zhang JY; You WY; Wang B; You PH; Lin KC; Yang T; Zeng YY
Hepatol Int; 2023 Dec; 17(6):1477-1489. PubMed ID: 37382760
[TBL] [Abstract] [Full Text] [Related]
16. Expression of PD-L1 and VISTA in Intraductal Papillary Mucinous Neoplasm With Associated Invasive Carcinoma of the Pancreas.
Mo S; Zou L; Hu Y; Chang X; Chen J
Mod Pathol; 2023 Sep; 36(9):100223. PubMed ID: 37244388
[TBL] [Abstract] [Full Text] [Related]
17. Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study.
Pan Y; Zhu X; Liu J; Zhong J; Zhang W; Shen S; Jin R; Liu H; Ye F; Hu K; Xu D; Zhang Y; Chen Z; Xing B; Zhou L; Chen Y; Zeng Y; Liang X; Kuang M; Song T; Xiang B; Wang K; Sun H; Xu L;
Front Immunol; 2023; 14():1138355. PubMed ID: 37180173
[TBL] [Abstract] [Full Text] [Related]
18. Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial.
D'Angelica MI; Ellis RJ; Liu JB; Brajcich BC; Gönen M; Thompson VM; Cohen ME; Seo SK; Zabor EC; Babicky ML; Bentrem DJ; Behrman SW; Bertens KA; Celinski SA; Chan CHF; Dillhoff M; Dixon MEB; Fernandez-Del Castillo C; Gholami S; House MG; Karanicolas PJ; Lavu H; Maithel SK; McAuliffe JC; Ott MJ; Reames BN; Sanford DE; Sarpel U; Scaife CL; Serrano PE; Smith T; Snyder RA; Talamonti MS; Weber SM; Yopp AC; Pitt HA; Ko CY
JAMA; 2023 May; 329(18):1579-1588. PubMed ID: 37078771
[TBL] [Abstract] [Full Text] [Related]
19. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK; Ueno M; Yoo C; Finn RS; Furuse J; Ren Z; Yau T; Klümpen HJ; Chan SL; Ozaka M; Verslype C; Bouattour M; Park JO; Barajas O; Pelzer U; Valle JW; Yu L; Malhotra U; Siegel AB; Edeline J; Vogel A;
Lancet; 2023 Jun; 401(10391):1853-1865. PubMed ID: 37075781
[TBL] [Abstract] [Full Text] [Related]
20. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNIcancer PRODIGE 23): Health-related quality of life longitudinal analysis.
Bascoul-Mollevi C; Gourgou S; Borg C; Etienne PL; Rio E; Rullier E; Juzyna B; Castan F; Conroy T
Eur J Cancer; 2023 Jun; 186():151-165. PubMed ID: 37068407
[TBL] [Abstract] [Full Text] [Related]
[Next]
